Hospital Universitari Arnau de Vilanova de Lleida

Author Of 1 Presentation

Neuropsychology and Cognition Poster Presentation

P0821 - Prevalence data of Cognitive Impairment in patients with Multiple Sclerosis of good clinical evolution in a cohort of patients from the city of Lleida (ID 1408)

Presentation Number
Presentation Topic
Neuropsychology and Cognition



Cognitive impairment (CI) appears in approximately 50% of cases with Multiple Sclerosis (MS), but we do not know how to determine the moment of this phenomenon and it is not associated with physical disability of the disease.


We set out to describe the prevalence of CI of the patients in our cohort who are defined as patients with good evolution by their clinical characteristics.


A cross-sectional study was conducted recruiting a total of 174 patients, of whom 111 had disease modifying treatments (DMT) (only first line treatments) and 63 patients without DMT (noDMT) and 69 healthy controls (HC) (recruitment not completed). All patients had to have an EDSS between 0 and 3.0 and a minimum of 5 years of evolution of the disease. All performed a neuropsychological examination that included a battery of tests to evaluate all cognitive domains (cutoff point percentile <5) and were classified as: normal or cognitive impairment and mild, moderate and severe according to the number of failed tests in each cognitive domain.


When we compared the patients vs the HC, we observed statistically significant differences p <0.019, regarding the general cognitive impairment (CI in controls: 19%; CI patients: 34%). The main difference between patients and HC was observed in the verbal memory domain p <0.014. When comparing patients with DMT with noDMT patients, we did not observe statistically significant differences between the groups (p <0.241), the percentages of patients with cognitive impairment were 31% for DMT patients and 40% in the group of patients without DMT. No significant differences were observed between the MS groups regarding the prevalence of mild, moderate or severe cognitive impairment.


Patients with good MS evolution have a higher prevalence of cognitive impairment than the normal population despite low physical disability and there is no difference between patients with DMT and patients without DMT with the same characteristics.